Biotech

All Articles

Neurocrine's KarXT competitor attacks in stage 2-- however only at low dose

.Neurocrine Biosciences has attained its hoped-for profile page in a stage 2 schizophrenia test, sup...

Vaderis' rare blood vessel ailment medication reduces nosebleeds

.Vaderis Therapies' objective to build the initial drug targeted specifically at a specific rare cap...

Navigator brings up $100M to cultivate new autoimmune pipeline

.Sat nav Medicines has equipped itself along with $100 million in set A funds as the young biotech g...

Duality looks for cash money for ADC trials as IPO wave spreads to Asia

.China's Duality Biotherapeutics has actually submitted (PDF) paperwork for a Hong Kong IPO, seeking...

YolTech sells China legal rights to genetics editing therapy for $29M

.4 months after Chinese genetics editing and enhancing firm YolTech Therapeutics took its cholestero...

Addex stock climbs after Indivior offers up to $300M for material

.Indivior is grabbing a little particle allosteric modulator designed to treat substance use problem...

Molecular Allies fine-tunes AML trial over 'suboptimal direct exposure'

.Molecular Companions has determined "suboptimal direct exposure" to its tetra-specific T-cell engag...

Despite mixed market, an equity capital resurgence could be coming in Europe: PitchBook

.While the biotech investment scene in Europe has slowed down quite complying with a COVID-19 backin...

8 months after a $213M fundraise, gene publisher Volume helps make reduces

.After increasing $213 million in 2023-- one of the year's most extensive exclusive biotech rounds--...

BioMarin develops exec group along with biotech veterinarians-- Chutes &amp Ladders

.Welcome to recently's Chutes &amp Ladders, our roundup of substantial management hirings, shootings...